Objective: To identify a biomarker profile associated with tumor response to chemoradiation (CRT) in locally advanced rectal cancer. Background: Rectal cancer response to neoadjuvant CRT is variable. Whereas some patients have a minimal response, others achieve a pathologic complete response (pCR) and have no viable cancer cells in their surgical specimens. Identifying biomarkers of response will help select patients more likely to benefit from CRT. Methods: This study includes 132 patients with locally advanced rectal cancer treated with neoadjuvant CRT followed by surgery. Tumor DNA from pretreatment tumor biopsies and control DNA from paired normal surgical specimens was screened for mutations and polymorphisms in 23 genes. Genetic biomarkers were correlated with tumor response to CRT (pCR vs non-pCR), and the association of single or combined biomarkers with tumor response was determined. Results: Thirty-three of 132 (25%) patients achieved a pCR and 99 (75%) patients had non-pCR. Three individual markers were associated with non-pCR; v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog mutation (P = 0.0145), cyclin D1 G870A (AA) polymorphism (P = 0.0138), and methylenetetrahydrofolate reductase (NAD(P)H) C677T (TT) polymorphism (P = 0.0120). Analysis of biomarker combinations revealed that none of the 27 patients with both tumor protein p53 (p53) and v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog mutations had a pCR. Further, in patients with both p53 and v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog mutations or the cyclin D1 G870A (AA) polymorphism or the methylenetetrahydrofolate reductase (NAD(P)H) C677T (TT) polymorphism (n = 52) the association with non-pCR was further strengthened; 51 of 52 (98%) of patients were non-pCR. These biomarker combinations had a validity of more than 70% and a positive predictive value of 97% to 100%, predicting that patients harboring these mutation/polymorphism profiles will not achieve a pCR. Conclusions: A specific biomarker profile is strongly associated with non-pCR to CRT and could be used to select optimal oncologic therapy in rectal cancer patients. ClinicalTrials.org Identifier: NCT00335816. (Ann Surg 2011;254:486-493) 
treatment for patients with locally advanced rectal cancer. This approach provides excellent tumor control and long-term survival [1] [2] [3] [4] but it is associated with measurable mortality, significant morbidity, and long-lasting sequela that may permanently impair quality of life. [5] [6] [7] [8] It is now evident that preoperative CRT is not equally beneficial for all rectal cancer patients. Some patients have a minimal response to CRT, whereas others have no detectable cancer cells in the primary tumor location or in regional lymph nodes in the surgical specimen. Patients with such a pathologic complete response (pCR) have a better prognosis compared with non-pCR patients. [9] [10] [11] [12] [13] [14] [15] If tumor response could be predicted before surgery, patients with resistant tumors could be spared CRT-related toxicity and expense. Furthermore, patients likely to achieve a pCR could potentially avoid the morbidity and functional consequences of TME. The benefit for these patients in terms of quality of life would be significant. Unfortunately, identifying responders and nonresponders to CRT before surgery remains a challenge.
Although tumor response to CRT depends on treatment-related factors, such as radiation dose and the type of chemotherapy administered, tumor biology appears to play the most important role in governing rectal cancer response to CRT. 16, 17 The search for molecular predictors of rectal cancer response to CRT has been an active area of research because such biomarkers could profoundly affect the clinical management of rectal cancer patients and influence the use of organ-preserving treatment strategies such as local excision or observation. Many studies have reported biomarkers of response to CRT, focusing on gene expression, mutations, and polymorphisms; [16] [17] [18] [19] [20] [21] [22] and although select genes or gene combinations have been identified as potential surrogates of response, none have been validated and incorporated into clinical practice.
In this study, we screened a series of 132 patients who were treated in a prospective rectal cancer trial for mutations and polymorphisms in 23 genes with previously reported roles in the pathogenesis of colorectal cancer. Our objective was to determine whether these molecular alterations alone or in combination were associated with response to CRT.
Treatment Protocol
Patients in all SGs were treated with CRT; 5-Fluorouracil (FU) 225 mg/m 2 /day for 7 days in continuous infusion, and a total of 50.4 Gy radiation. Patients in SG1 underwent TME an average of 6 weeks after completing CRT (standard of care). After CRT, patients in SG2 and SG3 with signs of stable disease or disease progression compared with baseline staging had surgery without further delay. All other patients received 2 and 4 cycles of additional chemotherapy (mFOLFOX-6), respectively; leucovorin 200 mg/m 2 or 400 mg/m 2 plus oxaliplatin 85 mg/m 2 by 2-hour infusion, followed by bolus of 5-FU 400 mg/m 2 and a 46-hour infusion of 5-FU 2400 mg/m 2 . Patients in SG2 and SG3 underwent TME an average of 11 and 16 weeks after completing CRT. The clinical outcomes for these patients are presented elsewhere. 24
Tumor Response to CRT
Pathologic complete response was defined as the complete absence of tumor cells from the rectal wall and regional lymph nodes by hematoxylin and eosin staining under microscopy. Tumor pathology was assessed by 2 independent pathologists and graded according to the recommendations of the American Joint Committee on Cancer. 23 For the purposes of the study, response was classified as either pCR or non-pCR based on the above criteria.
Sample Preparation and Molecular Analysis
Tumor DNA from pretreatment tumor biopsies and control DNA from paired normal surgical specimens for all patients was extracted as follows: 10 to 20 slides per patient sample from formalinfixed paraffin-embedded (FFPE) tumor biopsies and normal tissues were deparaffinized, hydrated, and stained with 0.2% methylene blue. A 27.5-gauge needle was then used to manually microdissect cells under inverted microscopy. Genomic DNA was extracted using the QIAamp DNA FFPE Tissue kit (Qiagen Inc, Valencia, CA) according to manufacturer's instructions with the after modifications; an extension of digestion time at 56 • C from 1 hour to 48 hours and the addition of three 20 μL aliquots of Proteinase-K at 4, 20, and 28 hours during digestion. DNA was then quantified by measuring absorbance at 260 nm.
PCR Analysis and Sanger Sequencing
Gene mutations and polymorphisms were screened by standard polymerase chain reaction (PCR) followed by Sanger sequencing (primer sequences shown in Supplementary Digital Content Table 1 available at http://links.lww.com/SLA/A167). PCR reactions consisted of 10 mM Tris-HCl (pH: 8.3), 50 mM KCl, 1.5 mM MgCl 2 , 5 mM primers, 200 mM dNTP, 0.1 μg/mL BSA, 0.5 U Amplitaq Gold (Applied Biosystems, Foster City, CA) plus 2 μL of tumor or control DNA in a total volume of 25 μL. Cycling conditions were 94 • C for 30 seconds, annealing for 30 seconds (specific temperatures shown in Supplementary Digital Content Table 1 available at http://links.lww.com/SLA/A167), and 72 • C for 1 minute, for a total of 40 to 45 cycles. An initial denaturation at 94 • C for 10 minutes and a final extension at 72 • C for 7 minutes were used. Two independently extracted DNA samples for each patient biopsy or surgical specimen were simultaneously amplified with a negative control (H 2 0). Two micro liter amount of each PCR reaction was analyzed in a 2% agarose gel to verify the presence of the expected amplified product. All sequencing reactions were carried out in both sense and antisense directions with PCR primers by Sanger sequencing and all mutations and polymorphisms were confirmed by sequencing 2 independently derived PCR products. Somatic mutations and polymorphisms were verified by comparison to paired normal surgical-specimen controls.
Statistical Analysis
Patient characteristics: To determine differences in clinical and pathological features between pCR and non-pCR patients, the Mann-Whitney U test was used for comparing means of continuous variables between groups and the 2-sided Fisher exact test and χ 2 test were used for testing the significance of differences in the distributions of categorical variables.
Characterizing biomarkers: For genes which could be classified as wild type or mutant, 2 × 2 analysis tables were constructed and genes were tested for association with tumor response using the Fisher exact test. For genes with multiple polymorphisms, each polymorphism was partitioned into 3 separate binary variables comparing a single allelic variation to the remaining combined alleles.
An exhaustive combinatorial analysis was performed to determine the association of each marker or combinations of markers with tumor response. All logical combinations were used (ie, logical operator AND, logical operator OR) among the binary variables including 1, 2, 3, or 4 markers at a time. More than 3 × 10 6 combinations were tested. This combinatorial approach allowed us to determine whether patients fail to respond if they carry at least 1 biomarker (OR) or whether the presence of numerous simultaneous biomarkers (AND/OR) are required to predict non-pCR.
False discovery rate was used to control for multiple comparisons. 25 Markers that remained significant after false discovery rate adjustment were internally cross-validated using 100 iterations, randomly selecting 70% of the subjects for "training," and 30%
Copyright © 2011 Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited. of the subjects for "testing". The Monte Carlo-based Cross-Validation for Logistic Regression in SAS cross-validation algorithm was used. 26 Finally the 2 × 2 tables and logistic regression scores were used to calculate the area under the curve of the receiver operating characteristic curve, and the sensitivity, specificity, and positive and negative predictive values of the molecular markers.
RESULTS

Patient Characteristics and Tumor Response
A total of 132 patients (58 in SG1, 52 in SG2, and 22 in SG3) were included in the analysis. Patient demographics stratified by pCR status for all patients are shown in Table 1 . Overall, 33 of 132 (25%) patients achieved a pCR. The 99 remaining non-pCR patients (75%) showed either a pathologic partial response (pPR) or had stable disease. No patients had disease progression. Seventeen (29%) patients in SG1 achieved a pCR, 10 (19%) in SG2, and 6 (27%) in SG3 (Table 1 ). There were no significant differences in tumor response between SGs, and there were no significant differences in clinical or pathological factors between pCR and non-pCR patients, or between SGs.
Individual Biomarker Analysis
Tumor DNA from pretreatment tumor biopsies and control DNA from paired normal surgical specimens for all patients was screened for mutations and polymorphisms in 23 genes (Supplementary Digital Content Table 1 available at http://links.lww.com/ SLA/A167). After screening and statistical analysis, 3 biomarkers were found to associate individually with non-pCR (Table 2) . v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations were more common in non-pCR patients compared with patients with a pCR (49% vs 24%, P = 0.0145), whereas the cyclin D1 (CCND1) G870A and methylenetetrahydrofolate reductase (NAP(P)H) (MTHFR) C677T polymorphisms were also associated with non-pCR. Specifically, patients with the CCND1 G870A (AA) polymorphism at the 870 locus of the CCND1 gene were significantly less likely to achieve a pCR compared with patients who carried either the G870A GA or G870A GG alleles at the same location (P = 0.0138). Of the total number of patients who carried the CCND1 G870A AA polymorphism in our patient population (19 of 132), 18 of 19 (95%) did not achieve a pCR. None of the patients that carried the MHTFR C677T (TT) polymorphism at the 677 locus of the MTHFR gene (14 of 132) achieved a pCR (P = 0.0120).
Of interest, mutations in tumor protein p53 (p53), v-raf murine sarcoma viral oncogene homolog B1 (BRAF), catenin (cadherinassociated protein), beta 1, 88kDa (CTNNB1) and phosphoinositide-3-kinase, catalytic, alpha polypeptide (PIK3CA), each previously reported to play a role in the pathogenesis of colorectal cancer, were not significantly associated with pCR in our patient population as stand-alone biomarkers ( Table 2) . No other single gene mutation or polymorphism was significantly associated with tumor response (Supplementary Digital Content Table 2 available at http://links.lww.com/SLA/A167).
Combination Biomarker Analysis
Next, mutation/polymorphism combinations for all molecular alterations were tested up to the order of 4 simultaneous markers. Approximately 3 million different combinations were tested and screened with false discovery rate correction to the P -value. After analysis, 6 different biomarker combinations were identified as both sufficiently prevalent in our patient population for meaningful validation and statistically associated with tumor response (pCR vs non-pCR) in a synergistic fashion ( Table 3 ). The majority of these biomarker combinations included mutations in both p53 and KRAS (5 of 6). The significance of this molecular profile is reflected in our patient population, where 27 of 132 patients had concurrent KRAS and p53 mutations and none had a pCR to CRT. Furthermore, in patients with both p53 and KRAS mutations or the CCND1 G870A (AA) polymorphism (n = 43) or the MTHFR C677T (TT) polymorphism (n = 52) the association with non-pCR was further strengthened (Table 3 ). When either polymorphism was added to the molecular profile, 51 of 52 (98%) patients failed to achieve a pCR to CRT.
Validation of Predictive Biomarker Profiles
The 4 most prevalent biomarkers (KRAS mutation, p53 mutation, CCND1 G870A [AA] polymorphism, MHTFR C677T [TT] polymorphism) based on a significant association with non-pCR individually or in combination were chosen for further validation to determine their value for predicting non-pCR. After internal validation, each biomarker combination analyzed had a validity of more than 70% ( Table 4 ). All combination sets had similar specificity and positive predictive values (97%-100%). The combination of all 4 markers-p53 and KRAS mutation, or the CCND1 G870A (AA) polymorphism, or the MTHFR C677T (TT) polymorphism-resulted in the highest area under the curve of the receiver operating characteristic curve (area under the curve = 0.74) and the highest sensitivity (52%) predicting that patients with this mutation/polymorphism profile will not achieve a pCR to CRT.
DISCUSSION
In this study, we identified gene mutations and polymorphisms that are individually associated with failure to achieve a pCR to CRT. We also found that when combined, these mutations and polymorphisms synergistically identify a subset of rectal cancer patients who do not develop a pCR in response to CRT with a high degree of accuracy.
Our results have immediate clinical relevance given that achieving a complete clinical response to CRT may be followed by an organ preservation approach such as local excision or observation in select patients with rectal cancer. Indeed a number of collaborative groups are already exploring the feasibility of these approaches. The American College of Surgeons Oncology Group recently completed a trial of CRT before local excision for T2N0 rectal cancer patients 27 and a wait-and-watch approach has been attempted at a small number of institutions. 28 The deferral of surgery for rectal cancer patients who develop a clinical complete response to CRT is also being studied prospectively by the National Cancer Research Network in collaboration with the Pelican Cancer Foundation in the United Kingdom. However, a clinical complete response does not always correlate with a pCR and patients with a clinical complete response after CRT may still have cancer cells in their surgical specimens. Our results show that biomarker profiling could help identify a subset of patients highly unlikely to develop a pCR to CRT and consequently help direct these patients away from organ preservation treatment strategies and toward clinically beneficial therapies such as TME.
KRAS is a key component of the mitogen-activated kinase pathway that is activated by cell surface receptors such as epidermal growth factor receptor (EGFR). These signals are then transduced to the nucleus where they phosphorylate and activate transcription factors leading to changes in gene expression. 29, 30 Mutant variants in the KRAS gene result in constitutive activation of its encoded protein, resulting in persistent activation of the mitogen-activated kinase pathway. 29, 30 KRAS is mutated in over a third of colorectal cancers and experimental evidence has shown that KRAS mutations can be found in the earliest tumor stage, and that once acquired, these mutations are preserved throughout the natural history of the tumor. 31, 32 Although previous studies on the prognostic value of KRAS mutation in patients with colorectal cancer have reported different results, 33 the recent discovery that KRAS mutation is a strong predictor of colorectal cancer response to the anti-EGFR monoclonal antibodies cetuximab and panitumumab 34, 35 has further established this gene as an important biomarker in colorectal cancer. Indeed KRAS mutation status is now routinely checked in every rectal cancer patient for potential candidacy of anti-EGFR therapy. 36 Few studies have evaluated KRAS as a biomarker for tumor response in rectal cancer patients treated with CRT and TME. Luna-Perez et al 37 described a series of rectal cancer patients treated with preoperative CRT and reported that tumors with wild-type KRAS were more likely to respond to CRT than tumors with mutant KRAS. However, these results should be interpreted with caution because of their small sample size, low rate of pCR, substandard radiotherapy, and the use of radiated cancer tissue for KRAS analysis. Bengala et al 38 also found that tumors with wild-type KRAS were more likely to respond to CRT compared with mutant KRAS (37% vs 11%) in 39 patients treated with cetuximab and CRT. Our data confirm these observations indicating that rectal cancers with wild-type KRAS are more likely to develop a pCR to 5-FU based CRT compared with tumors with mutant KRAS. Mutant KRAS may, therefore, be a biomarker for non-pCR in rectal cancer patients treated with CRT, with or without EGFR-inhibitors. However, other studies have reported contradictory results. 39, 40 Erben et al 39 found no correlation between KRAS mutation and tumor down-staging in 57 rectal cancer patients treated with cetuximab, irinotecan, and capecitabine in combination with pelvic irradiation. Similarly, Gaedcke et al 40 found no correlation between KRAS mutation and tumor down-staging in rectal cancer patients treated with 5-FU and oxaliplatin during radiation. However, these were smaller series, utilizing different radio-sensitizing drugs, and using different definitions of tumor response.
The CCND1 gene encodes the CCND1 protein, which is a key regulator of the cell cycle, promoting the transition from G1 to S phase and committing the cell to division and proliferation. 41 CCND1 expression is elevated in many types of cancers and its expression is regulated at multiple levels including transcription, translation, and protein stability and degradation. 41, 42 Polymorphisms within CCND1 contribute to its regulation and possibly to its oncogenic potential. Of more than 100 reported CCND1 polymorphisms, the GA polymorphism at locus 870 has received the most attention. This polymorphism is located at the exon 4/intron 4 boundary and has been linked to alternative gene splicing. The G allele codes for the optimal splicing, which produces the canonical form, termed CCND1a, whereas the A allele constrains exon 4 excision and allows translation into intron 4 resulting in a truncated CCND1b transcript that lacks the sequences required for degradation. The increase in the half-life in this variant form of CCND1 is consistent with an increase in cell proliferation, and the A allele has been associated with increased risk and advanced tumor stage in colorectal cancer, and a poor prognosis in a variety of cancers. 43 Li et al 44 recently reported that CCND1a is also important to elicit the DNA damage response that may result in DNA repair. Our findings, that patients homozygous for the A allele are less likely to respond to CRT, are consistent with the increased cell proliferation and reduced contribution to DNA damage response associated with CCND1b. However, other series have reported contradictory results. Ho-Pun-Cheung et al 45 reported better tumor response and lower risk of local recurrence associated with the AA allele among 65 patients with rectal cancer treated with preoperative radiotherapy. However in this smaller series, patients did not receive sensitizing chemotherapy, and response was based on histological tumor regression rather than on pCR.
Exposure of cells to DNA-damaging agents, such as ionizing radiation and chemotherapeutic drugs, elicits a complex set of acute cellular responses that involve the coupling of cell cycle arrest, DNA repair, and apoptosis. The central component of these responses is the product of the p53 gene, which modulates transcription of responsive genes involved in temporary or permanent growth arrest or apoptosis. Inactivation of p53 contributes to cellular resistance to DNA-damaging agents in vitro and in vivo. 46, 47 More than 50% of colorectal cancers harbor p53 mutations. Most of them are missense mutations, leading to the synthesis of a stable but inactive protein that accumulates in the nucleus of tumor cells. A number of studies have evaluated p53 mutations as predictors of response in rectal cancer patients treated with neoadjuvant therapy. [48] [49] [50] Although some studies found an association between mutant p53 and tumor response to radiation, 48, 49 other studies have not confirmed this association. 50 Our results concur with those series which found that mutant p53 alone is not associated with tumor response to CRT. However, we found that mutant p53 becomes a predictive biomarker of non-pCR when present in cancer cells harboring a KRAS mutation. In these cells, the combined mutation profile of these biomarkers may synergistically promote increased proliferation (KRAS mutation) coupled with tumor resistance to radiation and chemotherapy (p53 mutation) resulting in non-pCR.
The MTHFR gene codes for an enzyme that catalyzes conversion of 5,10-MTHF to 5-MTHF, the dominant circulating form of folate. 5,10-MTHF is used for the thymidylase synthase (TS)catalyzed conversion of deoxyuridylate to deoxythymidylate, important for DNA synthesis. A C-to-T transition in codon 677 of the MTHFR gene results in a genotypic variant associated with decreased enzyme activity. 51 Reduced MTHFR activity may increase the amount of 5,10-MTHF available for the TS enzyme, and increase the effect of TS inhibitors such as 5-FU, in individuals carrying this polymorphism. Although there are mixed results from studies investigating the effect of the MTHFR C677T polymorphism on colorectal cancer response to 5-FU, 52-54 2 studies suggest this polymorphism does affect rectal cancer response. 53, 54 Terrazzino et al 53 found that the likelihood of response for 122 patients treated with fluoropyrimidinebased CRT and surgery was higher among patients homozygous for the C allele compared to carriers of the T allele. Similarly, Cecchin et al 54 found that the T allele was associated with lower response rates in a series of 238 rectal cancer patients treated with fluoropyrimidinebased chemotherapy. 54 Our study found similar resistance to CRT associated with MTHFR C677T. Despite methodological differences between these 2 studies and our trial (both used radio-sensitizers in addition to fluoropyrimidines, defined response using tumor regression grade (TRG) rather than pCR, and used different CRT-to-surgery intervals), their combined results suggest that the MTHFR C677T (TT) polymorphism is associated with non-pCR to CRT.
There are a number of limitations to our study that warrant consideration. First, the sample size is relatively small and the study endpoint, pCR, occurred in only 25% of patients. Furthermore, although we used a common statistical cross-validation method, which has been applied extensively to biomarker-validation studies, 55 a larger independent series with more pCR and non-pCR patients will be important to validate these results. To address this we are continuing to collect specimens from additional patients in SG1-SG3 to further validate our results and extending our studies to an independent patient cohort. Second, although this is a prospective study with a homogenous patient population, the treatment regimen varied between the 3 SGs in both the use of adjuvant chemotherapy and the CRTto-surgery interval. Third, the tissue used to extract normal control DNA was obtained from the proximal resection margin of the surgical specimens. This tissue is usually outside the radiation field and it is unlikely that it received the full dose of radiation, but it was exposed to chemotherapy. Although we have recently shown that mutations in KRAS and p53 remain largely unchanged in rectal cancer after CRT, 56 the possibility of mutations arising due to treatment can not be totally excluded.
In conclusion, we have identified a biomarker profile that is associated with tumor resistance to CRT, evidenced by a lack of pCR. These findings are important because they help identify a subset of patients with rectal cancers who most likely will not respond to CRT and, therefore, should not be considered as candidates for organ preservation after CRT. 
DISCUSSANTS
R. D. Beauchamp (Nashville, TN):
You pointed out one problem with this study, which is that this is a relatively small group of patients, at 132 patients, of which only 33 experienced a pathologic complete response (pCR).
Another problem with this approach is that you are training and utilizing test sets internally on this same group of patients, creating a serious statistical problem. Before using this approach to actually advise patients on therapeutic alternatives, we need to validate these results in a larger group of patients who are independently studied.
In Tables 1 through 4 in your manuscript, you report 27 of 132 patients as possessing both p53 and KRAS mutations, and yet when you add the cyclin d1 (CCND1) polymorphisms, you had even more patients, 43. How can this latter number be greater than the 27 patients with p53 and KRAS mutations?
How did you select these 25 candidate genes from all those that are known to be mutated or have polymorphisms in colorectal cancer, and how were other genes excluded? For example, transforming growth factor-β receptor, bone morphogenetic protein receptors, SMAD family member 4, and phosphatase and tensin homolog, are all genes known to be mutated in colorectal cancer and may impact on outcome. What about microsatellite instability status, which can also impact upon response to therapy and outcome?
Third, you seem to imply that a partial response may not benefit the patient. Is this true? Many patients experience a dramatic clinical response but then not experience a complete pathological response. Do those patients not benefit from the neoadjuvant therapy? In other words, is sphincter preservation not an option without the therapy?
Was the absence of any of these mutations or polymorphisms associated with a pCR? Is it not the goal to identify the markers that can tell you which patients are actually going to experience a pCR? Finally, with respect to long-term follow-up, what are these patients' ultimate clinical outcomes as a function of these biomarkers?
Response From J. Garcia-Aguilar:
We agree with your suggestion of performing an external validation using an independent cohort of patients. For our study we performed a rigorous internal evaluation using solid methodology. However, the only way to make sure that these markers do indeed correlate with response is to validate them in an external set of patients; and that is what we intend to do in the future.
As to the number of patients with the different combinations of markers, we used all logical combinations (ie, logical operator AND, logical operator OR), including up to 4 markers at a time, to determine the association of biomarkers with tumor response. The model identified patients with p53 AND KRAS mutations (27 patients) OR CCND1 (19 patients) OR MTHFR (14 patients) polymorphisms, which is how we ended up with 52 patients in the 4-markers group.
To choose our markers, we searched the literature for gene mutations and polymorphisms previously associated with response or resistance to chemotherapy and radiation. This list is not comprehensive; there are other potential response biomarkers. Given the small size of the biopsy specimens, we chose those markers most likely to give us some positive results. There are other certainly genes we would like to study. Microsatellite instability is not very common in distal rectal cancers, and we saw microsatellite instability in only 4 patients in our series. We found no correlation between microsatellite instability and response or resistance.
There is now evidence that patients with locally advanced rectal cancer benefit from neoadjuvant therapy by improved local control and the possibility of sphincter preservation. Patients who experience a pathologic complete response seem to have improved survival compared with patients without complete response, but that does not mean that patients with partial response do not benefit from chemotherapy and radiation. We chose pCR as the end-point for our study because it is a more unequivocal outcome than other measures of tumor response such as tumor regression grade or tumor downstaging, which are more open to interpretation.
Our original intention was to search for tumor response biomarkers, rather than resistance. Instead, we found biomarkers of resistance. Considering that we looked at genetic alterations (activation of oncogenes such as KRAS and inactivation of tumor suppressor genes such as p53) that provide a biological advantage to the tumor cells, I am not surprised that those markers predict resistance rather than response. We intend to correlate these markers with the oncological outcomes of the patients.
DISCUSSANTS
P. Paty (New York, NY):
Your impressive molecular profiling identified genes that are important in the developmental biology of colon cancer and rectal cancer. However, just to play the devil's advocate, I think the results are somewhat disappointing in that the complete responders are molecularly heterogeneous and there were no positive predictor markers for a complete response. Your findings suggest that the injury induced by radiation and chemotherapy is so diffuse to the genome, RNA and proteins, that it is unlikely that 1 or 2 or a few markers will be predictive. There may be other factors, such as the size of tumors or the hypoxia of the tumor core, that predict response. This study confirms that the biology of rectal cancer is heterogeneous and complex.
Given the difficulty of finding positive predictors, what is the next logical step in your study? Is it to look for additional markers? Also, given that radiation is used generally to downstage tumors and gain local control rather than to induce a complete response, does your data help us with that indication? Who should get neoadjuvant radiation for downstaging?
Response From J. Garcia-Aguilar:
You raise a very important issue-we started by looking for predictors of response and ended with predictors of resistance. But if we reflect upon the biology of the tumor, these findings are not surprising. The genetic alterations that we chose to study as potential biomarkers involve molecular pathways that are essential for tumor development and progression. I am not surprised that they predict resistance rather than response. However, with the gene polymorphisms, it is possible that some of them may affect the metabolism of chemotherapeutic agents or DNA damage repair, which could predict response. We looked at a handful of them, but there are many more that we have not yet explored. Technology is advancing fast, and we should be able to look at the entire genome in every tumor specimen and compare it to normal DNA from the patient. This approach may help identify patients who are sensitive to chemoradiation.
On the contrary, markers of resistance may also have clinical applications; for example, KRAS mutations and anti-EGFR therapy
